Clinical trials: Cytarabine, completed
Brain and Central Nervous System Tumors, Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416819
- Testing
- filgrastim, rituximab, cytarabine
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Acute Leukemia, Relapsed, Acute Leukemia Refractory
CAV Regimen Bridging to HSCT for R/R AL
Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for acute leukemia (AL), relapsed or refractory (R/R) AL is still a big challenge.
- Trial name
- NCT05190549
- Testing
- CAV regimen bridging to HSCT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Relapsing-Remitting Multiple Sclerosis
High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
The purpose of this study is to determine the effectiveness of a new treatment for multiple sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal cord.
- Trial name
- NCT00288626
- Testing
- Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A…
- Conditions
- Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT05326516
- Testing
- Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 11 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
This phase I/II trial studies the side effects and the best dose of radiolabeled monoclonal antibody when given together with combination chemotherapy before stem cell transplant and to see how well it works in treating patients…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01921387
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Anemia, Leukemia
Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as leridistim and filgrastim increase the number of immune cells found in…
- Conditions
- Anemia, Leukemia, Neutropenia, Thrombocytopenia
- Trial name
- NCT00004215
- Testing
- filgrastim, leridistim, cytarabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop cancer cells from dividing so they stop growing and die.
- Trial name
- NCT00085709
- Testing
- gemtuzumab ozogamicin, observation, Cytosine arabinoside
- Where
- 279 sites in United States, Canada and 1 more
- Volunteers
- 637 people
- Sponsor
- SWOG Cancer Research Network
Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
- Trial name
- NCT00557193
- Testing
- Asparaginase, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 170 sites in United States, Australia and 2 more
- Volunteers
- 218 people
- Sponsor
- Children's Oncology Group
Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of azacitidine when given together with mitoxantrone, etoposide phosphate, and cytarabine in treating patients with acute myeloid leukemia that has returned after a period…
- Trial name
- NCT01249430
- Testing
- Azacitidine, Cytarabine, Etoposide Phosphate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
The goal of this clinical research study is to learn if the combination of clofarabine, cytarabine, and idarubicin can help to control Acute Myeloid Leukemia (AML) in patients who are between the ages of 18 and 60 years old.
- Trial name
- NCT01025154
- Testing
- Clofarabine, Idarubicin, Cytarabine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- ESHAP (NCT00732498)
- Testing
- Methylprednisolone, Etoposide, Cytarabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Arizona
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with more than one drug regimen may kill more tumor cells.
- Trial name
- NCT00003215
- Testing
- filgrastim, CHOP regimen, cyclophosphamide
- Where
- 12 sites in Austria, Germany and 3 more
- Volunteers
- 400 people
- Sponsor
- Swiss Cancer Institute
Leukemia, Myeloid, Acute
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
This study is a phase I/II study to determine the safety and efficacy of AMD3100 when combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory AML.
- Trial name
- AMD3100+MEC (NCT00512252)
- Testing
- AMD3100, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q)
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
This randomized phase II trial studies how well WEE1 inhibitor AZD1775 with or without cytarabine works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has spread to other places in the body and…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome
- Trial name
- NCT02666950
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Leukemia
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00070174
- Testing
- asparaginase, busulfan, cyclophosphamide
- Where
- 148 sites in United States, Australia and 3 more
- Volunteers
- 350 people
- Sponsor
- Children's Oncology Group
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
This is a Phase I study with a conditional cohort expansion phase to evaluate the feasibility of, and to obtain preliminary efficacy data about, pretreatment with Azacytidine (AZA) for 5 days followed by fludarabine/cytarabine…
- Trial name
- NCT01861002
- Testing
- Azacytidine, Fludarabine, Cytarabine
- Where
- 23 sites in United States, Australia and 1 more
- Volunteers
- 15 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
A Phase Ib/II multicentre open label study of bemcentinib (BGB324) as a single agent in participants with Acute Myeloid Leukemia (AML) or Myelodysplastic syndrome (MDS) or in a combination with cytarabine or decitabine in AML…
- Trial name
- NCT02488408
- Testing
- Bemcentinib, Cytarabine, Decitabine
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 122 people
- Sponsor
- BerGenBio ASA
Leukemia, Myelodysplastic Syndromes
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00107354
- Testing
- aldesleukin, therapeutic allogeneic lymphocytes, therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloblastic Leukaemia
Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
To reproduce or to improve the index of complete responses of protocol LMA-91 with a similar protocol, decreasing the dose of Idarubicin to try to reduce the deaths in induction
- Trial name
- NCT00464217
- Testing
- ARA-C, Idarubicin, Leucomax
- Where
- 24 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation